PharmaLive: DSM Biologics and Crucell Announce PER.C6 Licensing Deal With LFB Biotechnologies.

PharmaLive: DSM Biologics and Crucell Announce PER.C6 Licensing Deal With LFB Biotechnologies.: "SITTARD/LEIDEN, The Netherlands, July 25, 2007 - DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced a non-exclusive PER.C6� research licensing agreement with Paris, France-based LFB Biotechnologies. LFB Biotechnologies will use Crucell's technology to develop undisclosed antibodies. No financial details were disclosed."